Roivant Sciences Ltd.
ROIVNasdaq
$34.51
↑ +1.7%Jul 17 close · end-of-day
Price
1Y↑ +199.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$23.9B
Enterprise Value
$19.7B
P/E
—
P/S
2898.9
P/B
5.3
EV/EBITDA
—
PEG
—
FCF Yield
-3.2%
Dividend Yield
—
Revenue (TTM)
$8.3M
Net Income (TTM)
-$299.8M
Free Cash Flow (TTM)
-$758.6M
Gross Margin
—
Operating Margin
-6235.7%
Net Margin
-3629.2%
ROE
-6.6%
ROIC
-172.8%
Debt / Equity
—
Net Cash
$4.3B
Return 1Y
+196.2%
Company profile
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company that researches and develops medicines. The company was founded in 2014 and is based in London, the United Kingdom.
- CEO
- Matthew Gline
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 860
- Website
- roivant.com
Management & directors
- Gline MatthewCEO
- Sukhatme MayukhPresident & CIO
- Torti FrankPresident and Vant Chair
- Venker EricPresident & Immunovant CEO
- Humes JenniferChief Accounting Officer
- Pulik RichardCFO
Roles derived from SEC Form 4 filings.
Earnings
ROIV Q4 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.5M↓ -66.7%
Diluted EPS$0.34↓ -221.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | $23.8M | $55.3M | $31.5M | $32.7M | $29.1M | $8.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$1.1B | -$1.4B | -$906.8M | $4.5B | -$1.0B | -$515.1M |
| Net income | -$809.2M | -$845.3M | -$1.0B | $4.3B | -$172.0M | -$299.8M |
| Diluted EPS | — | -$1.26 | -$1.42 | $5.23 | -$0.24 | -$0.54 |
| Operating cash flow | -$552.1M | -$677.7M | -$843.4M | -$765.3M | -$839.5M | -$750.3M |
| Free cash flow | -$557.9M | -$695.2M | -$856.1M | -$766.6M | -$844.0M | -$758.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -4500.5% | -2444.8% | -2875.9% | 13746.9% | -3453.3% | -6235.7% |
| Net margin | -3400.9% | -1528.9% | -3200.2% | 13294.2% | -592.0% | -3629.2% |
| Line item | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.0M | $4.5M | $9.0M | $7.6M | $2.2M | $1.6M | $2.0M | $2.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$102.2M | -$341.7M | -$274.4M | -$285.0M | -$284.9M | -$306.2M | -$339.2M | $415.2M |
| Net income | $95.3M | -$230.2M | $169.4M | -$206.5M | -$223.4M | -$113.5M | -$265.9M | $303.0M |
| Diluted EPS | $0.12 | -$0.31 | $0.23 | -$0.28 | -$0.33 | -$0.17 | -$0.38 | $0.34 |
| Operating cash flow | -$192.8M | -$266.8M | -$207.3M | -$172.6M | -$204.4M | -$185.7M | -$196.5M | -$163.8M |
| Free cash flow | -$193.8M | -$267.8M | -$209.1M | -$173.4M | -$208.4M | -$193.5M | -$201.4M | -$165.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1279.5% | -7636.0% | -3042.6% | -3764.4% | -13130.0% | -19492.9% | -16966.1% | 16477.8% |
| Net margin | 1192.7% | -5143.8% | 1878.3% | -2727.5% | -10292.9% | -7225.9% | -13301.2% | 12023.6% |
Company news
Jul 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | MANCHESTER KEITH S | Sale | 200,000 | $35.45 | $7.1M | filing |
| 2026-06-30 | Gline Matthew· CEO | Tax withholding | 76,171 | $35.39 | $2.7M | filing |
| 2026-06-30 | Sukhatme Mayukh· President & CIO | Tax withholding | 46,878 | $35.39 | $1.7M | filing |
| 2026-06-30 | Torti Frank· President and Vant Chair | Tax withholding | 40,310 | $35.39 | $1.4M | filing |
| 2026-06-30 | MANCHESTER KEITH S | Sale | 12,380 | $35.28 | $436,766.40 | filing |
| 2026-06-30 | Gold Daniel Allen | Sale | 12,380 | $35.28 | $436,766.40 | filing |
| 2026-06-30 | QVT Financial LP | Sale | 12,380 | $35.28 | $436,766.40 | filing |
| 2026-06-30 | Fitzgerald Meghan | Sale | 10,000 | $34.90 | $349,000.00 | filing |
| 2026-06-30 | Fitzgerald Meghan | Option exercise | 10,000 | $8.80 | $88,000.00 | filing |
| 2026-06-29 | MANCHESTER KEITH S | Sale | 600,000 | $34.59 | $20.8M | filing |
| 2026-06-29 | Gold Daniel Allen | Sale | 600,000 | $34.59 | $20.8M | filing |
| 2026-06-29 | QVT Financial LP | Sale | 600,000 | $34.59 | $20.8M | filing |
| 2026-06-29 | QVT Financial LP | Sale | 200,000 | $34.44 | $6.9M | filing |
| 2026-06-29 | MANCHESTER KEITH S | Sale | 200,000 | $34.44 | $6.9M | filing |
| 2026-06-29 | Gold Daniel Allen | Sale | 200,000 | $34.44 | $6.9M | filing |
| 2026-06-29 | Epperly Melissa B, | Sale | 15,002 | $34.32 | $514,868.64 | filing |
| 2026-06-29 | Epperly Melissa B, | Sale | 2,748 | $34.71 | $95,383.08 | filing |
| 2026-06-29 | Epperly Melissa B, | Option exercise | 17,750 | $4.46 | $79,165.00 | filing |
| 2026-06-26 | Sukhatme Mayukh· President & CIO | Sale | 500,000 | $34.08 | $17.0M | filing |
| 2026-06-26 | MANCHESTER KEITH S | Sale | 325,000 | $34.07 | $11.1M | filing |
| 2026-06-26 | QVT Financial LP | Sale | 325,000 | $34.07 | $11.1M | filing |
| 2026-06-26 | Gold Daniel Allen | Sale | 325,000 | $34.07 | $11.1M | filing |
| 2026-06-26 | QVT Financial LP | Sale | 300,783 | $33.92 | $10.2M | filing |
| 2026-06-26 | Gold Daniel Allen | Sale | 300,783 | $33.92 | $10.2M | filing |
| 2026-06-26 | MANCHESTER KEITH S | Sale | 300,783 | $33.92 | $10.2M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.